- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03102671
Effectiveness of the HeartHab Application on Exercise Capacity in Patients With Coronary Artery Disease
HeartHab: a Prospective Cross-over Trial Investigating the Effectiveness of an App Based Telerehabilitation Program on Exercise Capacity, Lifestyle and Risk Factors in Patients With Coronary Artery Disease
Study Overview
Status
Conditions
Detailed Description
Study design and population This study is a prospective double-arm, non-pragmatic, cross-over, randomized controlled trial. Approximately 30 subjects will be selected retrospectively from the cardiology database of the Jessa Hospital Hasselt. Subjects who do not violate any of the predefined exclusion criteria and have provided informed consent will be randomly assigned in a 1:1 ratio to the treatment strategies (AB sequence or BA sequence).
After two months, each individual will be switched to the other treatment strategy.
Measurements At baseline, after two months (+14 days) and after four months (+14 days), a clinical assessment, medical history, current medication therapy, fasting blood sample, maximal cardiopulmonary exercise test, pulmonary function and three completed questionnaires (HeartQol, IPAQ and EQ-5D) will be collected of all patients. A fourth questionnaire will be completed by all the patients, focusing on the usability of the HeartHab-application.
Statistical analysis Data analysis will be performed using SPSS version 22 (SPSS Inc, Chicago, IL, USA) according to the intention-to-treat principle by assigned treatment group. Nonparametric alternatives will be used for parametric statistics in case assumptions for the latter are violated. The Shapiro-Wilk test will be used to assess normality. Paired t tests (parametric) or Wilcoxon signed rank tests (nonparametric) will be used for within-group analysis; independent t tests (parametric) or Mann-Whitney U tests (nonparametric) for between-group analysis. Chi-square tests will be used in case of categorical variables; Fisher's exact tests will be used when expected frequencies are small. The significance level for tests is 2-sided α=.05.
The cost-effectiveness evaluation will be conducted from a society and patient perspective, taking into account both intervention and health care resource costs. As the majority of patients will be retired, productivity losses due to illness-related absence from the workplace will not be taken into account.
Health care costs will be the aggregated costs of hospital admissions for cardiovascular reasons and also specialist visits and associated diagnostics. The cardiovascular rehospitalizations' related costs will be derived from invoices retrieved from the recruiting hospitals' financial departments. INAMI/RIZIV's nomenclature-based tariffs will define specialist visits and diagnostics denominations.
Quality adjusted life years (QALYs) will be used as a generic measure of effectiveness. Estimates of QALYs will be derived from the EQ-5D questionnaire. The EQ-5D scores will be converted to utility scores. The utility estimates will be converted to adjusted mean QALYs by calculating the area under the curve (AUC) utility estimates for all time intervals for each patient, weighted by the length of follow-up at that time interval. The change from baseline utility (adjusted differential incremental QALYs) will then be calculated, using the multiple regression model to control for baseline utility differences.
The incremental cost-effectiveness ratio (ICER) will be calculated (ICER¼(Cost intervention group - Cost control group)/(Effectiveness intervention group - Effectiveness control group)) to compare costs and outcomes (effectiveness) across both treatment groups. The incremental cost will be determined by the difference in total average cost per patient between the intervention group and control group. The incremental effectiveness will be estimated by the adjusted differential incremental QALYs.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hasselt, Belgium, 3500
- Jessa Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- History of coronary artery disease with or without intervention (PCI/CABG/conservative)
- History of a cardiac rehabilitation (CR) program
- Clinically stable without inducible ischemia or high risk ventricular arrhythmia, confirmed by the last available maximal ergospirometry test
- Age ≥18 years
- Willing and physically able to follow an app based telerehabilitation program and other study procedures in a four months follow-up period
- Evidence of a personally signed and dated informed consent, indicating that the subject (or legally-recognised representative) has been informed of all pertinent aspects of the study
- Possession of and/or able to use an Android smartphone
- Dutch speaking and understanding
Exclusion Criteria:
- Recent PCI or CABG procedure, and still included in a CR program
- Orthopedic, neurologic or any other pathologic condition which makes the patient physically unable to follow an app based telerehabilitation program
- Planned interventional procedure or surgery in the next four months
- Pregnant females
- Present cardiovascular complaints
- Participation in other cardiac rehabilitation program trials, focusing on exercise outcome
- Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study or a life expectancy of less than 4 months based on investigators judgement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AB sequence
Usual care followed by use of HeartHab application: Treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle), followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence.
|
Usual care (2 months) followed by the use of HeartHab application (two months)
|
Experimental: BA sequence
Use of HeartHab application followed by usual care: patients will be followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence, followed by treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle)
|
use of a mobile, app based multidisciplinary telerehabilitation program (2 months) followed by usual care (two months)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in VO2peak
Time Frame: day1
|
Exercise capacity is defined as the peak oxygen uptake, measured by CPET (cardiopulmonary exercise test)
|
day1
|
Change in VO2peak
Time Frame: month 2 + 14 days
|
Exercise capacity is defined as the peak oxygen uptake, measured by CPET (cardiopulmonary exercise test)
|
month 2 + 14 days
|
Change in VO2peak
Time Frame: month 4 + 14 days
|
Exercise capacity is defined as the peak oxygen uptake, measured by CPET (cardiopulmonary exercise test)
|
month 4 + 14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Risk factor profile: physiological parameter
Time Frame: day 1
|
Blood pressure
|
day 1
|
Risk factor profile: physiological parameter
Time Frame: day 1
|
Diabetes
|
day 1
|
Risk factor profile: physiological parameter
Time Frame: day 1
|
Overweight
|
day 1
|
Risk factor profile: physiological parameter
Time Frame: day 1
|
Smoking
|
day 1
|
Risk factor profile: physiological parameter
Time Frame: day 1
|
Physical activity
|
day 1
|
Risk factor profile: physiological parameter
Time Frame: month 2 + 14 days
|
Blood pressure
|
month 2 + 14 days
|
Risk factor profile: physiological parameter
Time Frame: month 2 + 14 days
|
Diabetes
|
month 2 + 14 days
|
Risk factor profile: physiological parameter
Time Frame: month 2 + 14 days
|
Overweight
|
month 2 + 14 days
|
Risk factor profile: physiological parameter
Time Frame: month 2 + 14 days
|
Smoking
|
month 2 + 14 days
|
Risk factor profile: physiological parameter
Time Frame: month 2 + 14 days
|
Physical activity
|
month 2 + 14 days
|
Risk factor profile: physiological parameter
Time Frame: month 4 + 14 days
|
Blood pressure
|
month 4 + 14 days
|
Risk factor profile: physiological parameter
Time Frame: month 4 + 14 days
|
Diabetes
|
month 4 + 14 days
|
Risk factor profile: physiological parameter
Time Frame: month 4 + 14 days
|
Overweight
|
month 4 + 14 days
|
Risk factor profile: physiological parameter
Time Frame: month 4 + 14 days
|
Smoking
|
month 4 + 14 days
|
Risk factor profile: physiological parameter
Time Frame: month 4 + 14 days
|
Physical activity
|
month 4 + 14 days
|
Generic health status: questionnaire
Time Frame: day 1
|
EQ5D
|
day 1
|
Exercise capacity: questionnaire
Time Frame: day 1
|
IPAQ
|
day 1
|
Quality of life: questionnaire
Time Frame: day 1
|
Heart QoL
|
day 1
|
Generic health status: questionnaire
Time Frame: month 2 + 14 days
|
EQ5D
|
month 2 + 14 days
|
Exercise capacity: questionnaire
Time Frame: month 2 + 14 days
|
IPAQ
|
month 2 + 14 days
|
Quality of life: questionnaire
Time Frame: month 2 + 14 days
|
Heart QoL
|
month 2 + 14 days
|
Generic health status: questionnaire
Time Frame: month 4 + 14 days
|
EQ5D
|
month 4 + 14 days
|
Exercise capacity: questionnaire
Time Frame: month 4 + 14 days
|
IPAQ
|
month 4 + 14 days
|
Quality of life: questionnaire
Time Frame: month 4 + 14 days
|
Heart QoL
|
month 4 + 14 days
|
Cardiovascular events: clinical assessment
Time Frame: day 1
|
Collection of adverse events during follow up visit
|
day 1
|
Cardiovascular events: clinical assessment
Time Frame: month 2 + 14 days
|
Collection of adverse events during follow up visit
|
month 2 + 14 days
|
Cardiovascular events: clinical assessment
Time Frame: month 4 + 14 days
|
Collection of adverse events during follow up visit
|
month 4 + 14 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Paul Dendale, prof. dr., Hasselt University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HeartHab-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Usual care followed by the use of HeartHab application
-
University Hospital, ToulouseRecruitingPersonality Disorders | Substance Related DisorderFrance
-
Brno University HospitalRecruiting
-
University of PittsburghMedtronicCompleted
-
Universidad de AntioquiaFarmacias PasteurNot yet recruiting
-
Hôpital le VinatierRecruiting
-
Odense University HospitalRigshospitalet, Denmark; Danish Cancer SocietyRecruiting
-
University of JenaUnknown
-
Stanford UniversityCompletedDepressive Disorder | Depression | Depression, Postpartum | Anxiety | Telemedicine | Mental Health | Cognitive TherapyUnited States
-
Botanee Group Co., Ltd.Active, not recruitingSkin Manifestations | Wrinkle | Skin | Skin LaxityChina
-
Botanee Group Co., Ltd.Enrolling by invitationSkin Manifestations | Wrinkle | PhotoagingChina